Axim Biotechnologies, Inc. · OTC:AXIM
Axim Biotechnologies — Investor Presentation (June 2017)
25 slides from Axim Biotechnologies's investor presentation, June 2017
Slide 1: Management Presentation June 2017
Management Presenta,on June 2017
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Axim’s management and are subject to si
Slide 3: Problem
Problem • Smoke from any source is harmful to lung health • Smoke from marijuana combus6on has been shown to contain many of the same toxins, irritants and carcinogens as tobacco smoke • Marijuana smokers tend to inhale more deeply and hold their breath longer than cigare=e smokers, which leads to a
Slide 4: Problem
Problem • Smoking marijuana causes chronic bronchi6s and injure the cell linings of the large airways, leading to symptoms such as chronic cough, phlegm produc6on, wheezing and acute bronchi6s • Smoking marijuana can harm more than just the lungs and respiratory system - it can also affect the immune
Slide 5: Opportunity
Opportunity • We are providing a full-package solu6on to CBN- pharma space: (IP, organiza6on, R&D, logis6cs, legal framework, products and ongoing extensive research) • We developed the best oral, trans-mucosal, controlled release delivery system vastly superior to any others on the market • 14-year
Slide 6: Characteristics of an Ideal Delivery System
What are the Characteris,cs for an Ideal Delivery System? • Improved/ similar PK/PD profile to smoked form • Broader Therapeu6c Index • Control of release depending on indica6ons (rapid vs. depot) • Provision of addi6onal benefits besides the ones directly a=ributed to the API • Reduced cost 6
Slide 7: Where Are We Today (Delivery Forms)?
Where are We Today (delivery forms)? • Smoking • Evapora6on (Vulcan™) • Oral spray (Sa6vex™) • Inges6ble forms (tablets, capsules, oils and edibles) • Trans mucosal, Controlled Release (CanChew™, CanChew Plus™, MedChew™, HempChew™) • Flotex-C™ floatable capsule (super-slow release) • Suppositories (S
Slide 8: Why Chewing Gum?
Why Chewing Gum? • Extensive territory of the oro-pharyngeal mucosae for rapid/ controlled absorp6on of the API and avoidance of 1’st pass metabolism • Social acceptance (NO cigare=es, bongs, etc.) • Salivary produc6on • Teeth cleaning effect 8
Slide 9: Beneficial Effects of the Act of Mastication
Beneficial effects of the act of mas,ca,on: • Improved cerebral circula6on • S6mula6on of basal ganglia • CV-s6mula6on • De-stress or “eustress” • Hypothalamic-hypophyseal-adrenal axis (HPA) coordina6on/ a=enua6on • Memory coordina6on/ improvement • Neuroprotec6on • Analgesic effect • Physical exercise
Slide 10: Challenges and Solutions
Challenges and Solu,ons • Control of release: Introduc6on of cellulose as carrier (IP AXIM) • Increase purity through extrac6on: Heptane extrac6on method (IP AXIM) • Conversion to hydrophilic form: Freeze-dried/ blended formula6on (IP AXIM) • Controlled 24-hr release for condi6ons such as IBD, IBS,
Slide 11: Value Proposition
Value Proposi,on • The average market cap of the 3-leading med. CBN public companies (GWPH, INSY, ZYNE) is $1.3 billion* • The market cap of AXIM is $586,112,469; provides more a=rac6ve upside for investors* *Source: Google Finance, data as of 05/30/2017 11
Slide 12: Why Is AXIM Better Than the Competition?
Why is AXIM BeRer Than the Compe,,on? 1. Established full chain of produc6on (extrac6on, purifica6on, conversion, microencapsula6on, etc.) 2. Possess its own, proprietary formula6ons undergoing clinical trials for a number of indica6ons 3. Have developed nutraceu6cal product which is on the market in
Slide 13: Underlying Magic
Underlying magic • Every step in the produc6on process is based on AXIM’ IP. • The technological secret is a unique delivery system where 1+1=>3 13
Slide 14: Business Model
Business Model • The leader in the space today is GW Pharma which has 1 ½ products on the market (Sa6vex™ and Epidiolex™) • We have formulated over 20 diversified products and possess 17 patents and 20 TM’ • Strategic rela6onships with big-pharma and distributors for drug development/ licensing 14
Slide 15: Go-To-Market Plan
Go-To-Market Plan • Lead product is MedChew Rx® for Pain and Spas6city in MS. Planned to be registered with EMA, FDA by end of 2018. Clinical trials at VUAm, U. Plymouth, and a center in the USA • Plaworm for delivery of any med’ for any neurodegenera6ve Ds’ • CanChew+® and CanChew Rx® : Indic. For
Slide 16: Competitive Analysis
Compe,,ve Analysis • Procurement of Raw materials (GMP/ FDA/ EMA grade) • Nutraceu6cal • Pharmaceu6cal • Cosme6cs • Oral Care • R&D • Manufacturing 16
Slide 17: Strong Growth Platforms, $1.0 Billion Global Brand Portfolio By 2025
Strong Growth PlaVorms, $1.0 Billion Global Brand PorVolio By 2025 Nutraceu6cal Pharmaceu6cal Oral Health Cosme6c $203M 6%ᵃ $197M 4%ᵇ $115M 7%ᶜ $77M 5%ᵈ Alterna6ve Energy Phytoplant / Botanicals Manufacturing Research & Development $1.3M 6%ᵉ $86M 16%ᶠ $284M 16%ᶢ NMʰ 16%ᶦ Axim 2025 revenue es6mates 2
Slide 18: Management Team
Management Team Axim is Led by a Credible and Proven Management Team George Anastassov, MD, DDS, MBA § Chairman, Chief Execu6ve and Financial Officer § Co-founder, CEO of CanChew Biotechnologies, LLC and Director and GP of Sanammad Founda6on and Sanammad Pharmaceu6cals, BV § Research and Development i
Slide 19: World Renowned Advisory Board
World Renowned Advisory Board Prof. Renger Whitkamp Prof. John Zajicek Dr. Arno Hazekamp Warren C. Hutchins Dr. Murad A. Sunalp Dr. Jacques F. Mels Marvin Washington Joe Grace Dr. Ilya Reznik Dr. Robert Ritch Dr. Emil Engles Dr. Donald Abrams 19
Slide 20: Clinical Development Program
Clinical Development Program 20
Slide 21: IBS Clinical Trial University of Wageningen (NL)
IBS Clinical Trial University of Wageningen (NL) PP01: 10 mg CBD PP04: 30 mg CBD Phase 2 Clinical trial: • Drug: CanChew gum 50mg CBD; dosage: up to 6 gums/day • Pa6ents: 40 subjects (18-55 yrs) • Dura6on: 8 weeks randomized double blind cross over trial • Endpoints: pain reduc6on (VAS); QOL (IBD-QO
Slide 22: MedChewRx Clinical Trial on MS Patients-1
MedChewRx Clinical Trial on MS Pa,ents-1 Phase 1: PK/PD Biocomparison trial: • Drug: MedChewRx 5 mg THC/5 mg CBD; Sa6vex 2,7 mg THC/2,5 mg CBD • Healthy volunteers: 15 (18-55 yrs) • Phase 1 center: QPS Phase 1 unit Groningen (NL) • Treatments: No MedChewRx Sa,vex Charcoal A SD 10 min B SD 20 min C S
Slide 23: MedChewRx Clinical Trial on MS Patients-2
MedChewRx clinical trial on MS pa,ents-2 Phase 2/3: • Drug: MedchewRx 5 mg THC/5 mg CBD • Pa6ent: 100 (18-55 yrs) • Mul6center: *Switzerland, VU Amsterdam, UK Plymouth, USA. • Dura6on: screening phase (1 wk)àopen 6tra6on effec6ve dose (2 wk)àdouble blind cross over period each (2 wk); total 7 wk + fo
Slide 24: Axim Today/Tomorrow Projections
Axim Today/Tomorrow Projec,ons: Tomorrow § Ver6cally-integrated supply chain § NYSE or NASDAQ § 10 - 15 commercial products * § R&D, Pharmaceu6cal, Nutraceu6cal, Manufacturing, Farming and Bio- coal, Oral Care Cosme6c consumer products* § 10+ patents, 20+ trademarks* § Full manufacturing capabili6es
Slide 25: END
END For further information, please contact: Dr. George E. Anastassov, CEO Tel. +1 844 294 6246 [email protected] www.aximbiotech.com North American Address: European Address: 18 East 50th Street, 5 Floor Boelewerf 32, Unit 3 New York, NY 10022 2987 VD Ridderkerk, The Netherlands +1 844 29
Axim Biotechnologies — Investor Presentation (June 2017) on 6ix